Sirolimus: Efficacy and Complications in Children With Hyperinsulinemic Hypoglycemia: A 5-Year Follow-Up Study

INTRODUCTION: Sirolimus, a mammalian target of rapamycin inhibitor, has been used in congenital hyperinsulinism (CHI) unresponsive to diazoxide and octreotide. Reported response to sirolimus is variable, with high incidence of adverse effects. To the best of our knowledge, we report the largest grou...

Descripción completa

Detalles Bibliográficos
Autores principales: Maria, Güemes, Antonia, Dastamani, Michael, Ashworth, Kate, Morgan, Sian, Ellard, Sarah, Flanagan E, Mehul, Dattani, Pratik, Shah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2019
Materias:
Meta-Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411415/
https://www.ncbi.nlm.nih.gov/pubmed/30882046
http://dx.doi.org/10.1210/js.2018-00417

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411415/
https://www.ncbi.nlm.nih.gov/pubmed/30882046
http://dx.doi.org/10.1210/js.2018-00417

Ejemplares similares